Latest Breaking News On - History study - Page 12 : comparemela.com

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial Highlights: Alterity receives positive guidance from the European Medicines Agency’s Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence with Alterity’s plan to target early stage MSA patients. Endorsement on selection of biomarker endpoints to assess pathological hallmarks of MSA. Agreement that ATH434 has potential as a disease modifying treatment. MELBOURNE, Australia and SAN FRANCISCO, June 23, 2021 /PRNewswire/ Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ) has received guidance from the European Medicines Agency (EMA) regarding key aspects of the Company’s Phase 2 clinical trial for investigational drug ATH434 in the treatment of Multiple System Atrophy (MSA).

David stamlerCompany phaseVanderbilt university medical centerDrug administrationEuropean unionEuropean medicines agencyAlterity therapeutics limitedAlterity therapeuticsMedicinal productsHuman useMultiple systemMultiple system atrophyHistory studyProgressive supranuclear palsyநிறுவனம் கட்டம்வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ மையம்